SYRE — SPYRE THERAPEUTICS INC

Ownership history in BRAIDWELL LP  ·  9 quarters on record

This page tracks every 13F SEC filing in which BRAIDWELL LP reported a position in SPYRE THERAPEUTICS INC (SYRE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.85% (2024 Q2)
Avg. % of fund
1.36%
First filed
2023 Q4
Last filed
2025 Q4
Quarters held
9
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 1,634,615 -943,789 -36.6% 1.71% $53.5M $32.76
2025 Q3 UNCHANGED 2,578,404 — 0% 1.28% $43.2M $16.76
2025 Q2 UNCHANGED 2,578,404 — 0% 1.32% $38.6M $14.97
2025 Q1 UNCHANGED 2,578,404 — 0% 1.46% $41.6M $16.14
5 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    SYRE price (monthly, adj. close)

Other funds also holding SYRE

As of 2025 Q4 — sorted by position size

Remedium Capital Partners, LLC 28.03% Fairmount Funds Management LLC 3Y 10.02% CAXTON CORP 3Y 7Y 6.83% VR Adviser, LLC 3Y 5.96% Commodore Capital LP 3Y 5.21% TANG CAPITAL MANAGEMENT LLC 3Y 7Y 3.06% Affinity Asset Advisors, LLC 3Y 2.67% B Group, Inc. 2.42% TCG Crossover Management, LLC 3Y 2.06% PERCEPTIVE ADVISORS LLC 3Y 7Y 1.79%
← Back to BRAIDWELL LP Holdings